Radius Pharmaceuticals, Inc.

Ellipses Pharma Limited

Nuvation Bio Inc.

Chris P Miller

Gary Hattersley

Jamal Saeh

Ziyang Yu

Teeru Bihani

Sarvajit Chakravarty

Son Minh Pham

Jeremy D Pettigrew

Jayakanth Kankanala

Anjan Kumar Nayak

Jiyun Chen

Anup Barde

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Estrogen receptor-modulating compounds

A method for treating AR+ breast cancer in a subject comprising administering to the subject an AR agonist (e.g., SARMs such as RAD140), or in combination with one or more therapeutic agents selected from the group consisting of cdk4/6 inhibitors, m-TOR inhibitors, PI3k inhibitors, PARP inhibitors, BCL-2 inhibitors, and MCL-1 inhibitors.

AR+breast cancer treatment methods

AR+ breast cancer treatment methods

Novel bromodomain and extraterminal domain (BET) inhibitors and to therapeutic methods of treating conditions and diseases using these novel BET inhibitors are provided.

Heterocyclic compounds as BET inhibitors

This invention provides compounds of formula I, pharmaceutical compositions comprising a compound of formula I and a pharmaceutically acceptable excipient, methods of modulating the androgen receptor, methods of treating diseases beneficially treated by an androgen receptor modulator (e.g., sarcopenia, prostate cancer, contraception, type 2 diabetes related disorders or diseases, anemia, depression, and renal disease) and processes for making compounds and intermediates useful in the preparation of same.

Selective androgen receptor modulators

Growing community of inventors

Waltham, MA, United States of America

Chris P Miller